Previous 10 | Next 10 |
2023-04-11 13:03:15 ET Summary Arcturus is executing well, utilizing strategic partnerships with CSL and Meiji to de-risk its financial position. The company has reinforced its management team by appointing a CMO and CDO, bringing valuable experience to the company's pipeline deve...
2023-03-29 10:05:07 ET Gainers: Kodiak Sciences ( KOD ) +19% . Arcturus Therapeutics ( ARCT ) +16% . Erasca ( ERAS ) +15% . G Medical Innovations ( GMVD ) +15% . Atai Life Sciences ( ATAI ) +13% . Losers: ProQR The...
2023-03-28 19:02:04 ET Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2022 Earnings Conference Call March 28, 2023 04:30 PM ET Company Participants Neda Safarzadeh - IR Joseph Payne - President & CEO Andrew Sassine - CFO Padmanabh Chivukula - Chief Scienti...
2023-03-28 18:08:06 ET A combination of quarterly results beating on the top and bottom lines and an extension of its cash runway into 2026 has propelled Arcturus Therapeutics ( NASDAQ: ARCT ) ~21% higher in after-hours trading. The runway extension is due to the ...
2023-03-28 16:02:10 ET Arcturus Therapeutics press release ( NASDAQ: ARCT ): Q4 EPS of $4.33 may not be comparable to consensus of $1.23. Revenue of $160.29M (+2663.6% Y/Y) beats by $79.77M . For further details see: Arcturus Therapeutics EPS of $4.33, revenu...
$200 million upfront payment received in December 2022 from CSL collaboration Achieved $90 million in development milestones in March 2023 under CSL collaboration ARCT-154 Phase 3 COVID-19 booster trial enrollment completed in Japan Multiple patients enrolled in ARCT-8...
2023-03-27 17:35:56 ET Arcturus Therapeutics ( NASDAQ: ARCT ) is scheduled to announce Q4 earnings results on Tuesday, March 28th, after market close. The consensus EPS Estimate is $1.23 and the consensus Revenue Estimate is $80.52M (+1288.3% Y/Y). Over the last 3 mont...
2023-03-27 17:35:09 ET Major earnings expected after the bell on Tuesday include: Micron Technology ( MU ) Lululemon Athletica ( LULU ) Ideanomics ( IDEX ) Emeren Group ( SOL ) nCino ( NCNO ) For further details see: Notable earnings after...
Arcturus to present at the Guggenheim Healthcare Talks: Genomic Medicines & Rare Disease Day, April 3, 2023 Arcturus Therapeutics Holdings Inc. (the “Company,” “Arcturus,” Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused...
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare disease...
News, Short Squeeze, Breakout and More Instantly...
Arcturus Therapeutics Ltd. Company Name:
ARCT Stock Symbol:
NASDAQ Market:
Arcturus Therapeutics Ltd. Website:
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and medicines to treat unmet medical needs within liver and respiratory rare diseases, toda...
2024-07-02 10:15:03 ET Piper Sandler analyst issues OVERWEIGHT recommendation for ARCT on July 2, 2024 08:19AM ET. The previous analyst recommendation was Overweight. ARCT was trading at $23.66 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
ARCT-810 Phase 2 study completed enrollment at 0.3 mg/kg dose level in Europe with data expected later this year ARCT-810 to expand Phase 2 clinical program in the U.S. to enroll patients with more severe disease ARCT-032 IND for Phase 2 multiple ascending dose study to be submitt...